Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. carries a market capitalization of 12.69B, placing it among publicly traded companies globally. Its enterprise value stands at 9.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.69B |
| Enterprise Value | 9.56B |
Share Statistics
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. currently has 523.58M shares outstanding.
| Shares Outstanding | 523.58M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 31.27. The price-to-sales ratio is 11.02, and the price-to-book ratio stands at 5.22.
| PE Ratio | 31.27 |
| PS Ratio | 11.02 |
| PB Ratio | 5.22 |
| P/TBV Ratio | 4.52 |
| P/FCF Ratio | 81.29 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 26.44 and an EV/FCF ratio of 71.55. The EV/Sales ratio of 9.75 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 26.44 provides insight into valuation relative to core operating earnings.
| EV / Sales | 9.75 |
| EV / EBITDA | 26.44 |
| EV / EBIT | 26.44 |
| EV / FCF | 71.55 |
Financial Position
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. maintains a current ratio of 9.34, meaning it holds 9.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.81, indicating moderate leverage, while an interest coverage ratio of 424.94 demonstrates strong ability to service its debt obligations.
| Current Ratio | 9.34 |
| Quick Ratio | 7.56 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | 0.06 |
| Interest Coverage | 424.94 |
Financial Efficiency
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. posts a return on equity of 17.69 and a return on invested capital of 12.10.
| Return on Equity (ROE) | 17.69 |
| Return on Assets (ROA) | 12.63 |
| Return on Invested Capital (ROIC) | 12.10 |
| Return on Capital Employed (ROCE) | 17.10 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.79 |
Taxes
Over the trailing twelve months, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. has paid 61.95M in income taxes, reflecting an effective tax rate of 15.72.
| Income Tax | 61.95M |
| Effective Tax Rate | 15.72 |
Stock Price Statistics
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s stock has gained approximately 14.44759% over the past 52 weeks. The 50-day moving average sits at 23.45, while the 200-day moving average is 27.54.
| Beta (5Y) | N/A |
| 52-Week Price Change | 14.44759% |
| 50-Day Moving Average | 23.45 |
| 200-Day Moving Average | 27.54 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. generated 980.37M in revenue and converted that into 345.60M in net income, yielding earnings per share of 0.63. EBITDA reached 361.71M, while operating income came in at 361.71M.
| Revenue | 980.37M |
| Gross Profit | 933.53M |
| Operating Income | 361.71M |
| Pretax Income | 394.09M |
| Net Income | 345.60M |
| EBITDA | 361.71M |
| EBIT | 361.71M |
| Earnings Per Share (EPS) | 0.63 |
Balance Sheet
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. holds 1.36B in cash and equivalents against 20.79M in total debt, resulting in a net debt position of -1.10B. Total book value stands at 2.07B, with working capital of 1.50B providing operational flexibility.
| Cash & Cash Equivalents | 1.36B |
| Total Debt | 20.79M |
| Net Debt | -1.10B |
| Equity (Book Value) | 2.07B |
| Book Value Per Share | 3.95 |
| Working Capital | 1.50B |
Cash Flow
After subtracting -132.93M in capital expenditures, free cash flow totaled -132.93M - equivalent to -0.25 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -132.93M |
| Free Cash Flow | -132.93M |
| FCF Per Share | -0.25 |
Margins
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. operates with a gross margin of 95.22, reflecting its pricing power and cost economics. The operating margin of 36.90 and net profit margin of 35.25 provide insight into operational efficiency.
| Gross Margin | 95.22 |
| Operating Margin | 36.90 |
| Pretax Margin | 40.20 |
| Profit Margin | 35.25 |
| EBITDA Margin | 36.90 |
Dividends & Yields
The company's payout ratio of 46.87 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.29 |
| Dividend Yield | N/A |
| Payout Ratio | 46.87 |
| Shareholder Yield | 1.86 |
| FCF Yield | 1.23 |
Stock Splits
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s most recent stock split took place on May 8, 2019 with a 5:9 split ratio.
| Last Split Date | 5/8/2019 |
| Split Ratio | 5:9 |
Scores
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. posts an Altman Z-Score of 31.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 31.34 |